Biontech and Genmab's collaboration goes deeper than previously said

The partnership between Genmab and Biontech extends beyond the three current clinical projects evident in their pipelines. The two firms are also collaborating on a number of preclinical candidates that have yet to reach the public’s eye. (Corrected)

Özlemtech, sees partnership opportunities in Denmark beyond the existing collaboration with Danish Genmab | Photo: Biontech/PR

(Correction: The article previously stated that the candidate Gen1056 was already in a clinical phase. This now reads that the candidate is headed to clinic).

The partnership between Danish Genmab and Biontech goes far deeper than what the public is privy to, two Biontech founders, Ugur Sahin and Özlem Türeci, tell MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs